{"id":390572,"date":"2018-10-17T00:00:00","date_gmt":"2018-10-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0019-2018-biopharma-breast-cancer-unmet-need-metastatic-hr-positive-her2-negative-us-eu-2018\/"},"modified":"2026-04-30T23:43:45","modified_gmt":"2026-04-30T23:43:45","slug":"unneon0019-2018-biopharma-breast-cancer-unmet-need-metastatic-hr-positive-her2-negative-us-eu-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unneon0019-2018-biopharma-breast-cancer-unmet-need-metastatic-hr-positive-her2-negative-us-eu-2018\/","title":{"rendered":"Breast Cancer | Unmet Need | Metastatic HR-Positive\/ HER2-Negative | US\/EU | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Despite the number of therapy options available, metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women. Additionally, a significant need exists for therapies following hormone resistance in later lines. While the introduction of targeted therapies has helped to improve patient outcomes, a number of unmet needs and treatment gaps persist. Several emerging therapies are also poised to launch in the near term, further increasing competition in a crowded market. As this competition in\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer intensifies, novel therapies should more effectively address existing unmet needs to distinguish themselves from their rivals.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What are the treatment drivers most likely to influence a therapy\u2019s uptake for metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer?<\/li>\n<li>How do current therapies perform on key drug attributes for metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer?<\/li>\n<li>What are the prevailing areas of unmet need and hidden opportunities in this patient population?<\/li>\n<li>What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price when considering hypothetical new treatment options in metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.<\/p>\n<p><strong>Markets covered:<\/strong>\u00a0United States, France, Germany, United Kingdom.<\/p>\n<p><strong>Primary research:\u00a0<\/strong>Survey of 60 medical oncologists in the United States and 30 medical oncologists in Europe.<\/p>\n<p><strong>Key drugs:<\/strong>\u00a0Ibrance, letrozole, anastrozole, Faslodex, Kisqali, Verzenio, Afinitor, and exemestane.<\/p>\n<p><strong>Key metrics:<\/strong><\/p>\n<ul>\n<li>Stated versus derived analysis of U.S. and European physician prescribing behavior.<\/li>\n<li>Conjoint analysis with U.S. and European physicians includes market simulator.<\/li>\n<li>Assessment of current drug performance against treatment drivers and goals.<\/li>\n<li>Physician perceptions of unmet need in metastatic\u00a0<abbr title=\"hormone receptor\">HR<\/abbr>-positive\u00a0<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer and related diseases\/subpopulations.<\/li>\n<li>Analysis of remaining drug development opportunities.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390572","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390572\/revisions"}],"predecessor-version":[{"id":393696,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390572\/revisions\/393696"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}